Clinical evaluation of the SSSLTVPWY peptide labeled with 99m TC

Clinical evaluation of the SSSLTVPWY peptide labeled with 99m TC to determine HER2 status for the treatment of patients with Breast Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180310039019N1

Enrollment

Registered

2018-03-21

Start date

2018-05-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast of unspecified site, female

Interventions

Intervention group: imaging at 1,2,3 and 4 hours after the intravenous injection of 740 MBq of radiopeptide.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female Primary breast cancer Size greater than 2cm Without any history of biopsy

Exclusion criteria

Exclusion criteria: Renal failure Liver dysfunction Pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Radiotracer uptake by breast cancer. Timepoint: Imaging of the breast at 1,2,3 and 4 hours after the administration of the Radiopeptide. Method of measurement: With imaging.	—

Secondary

Measure	Time frame
Distribution of radiopeptide in other tissues. Timepoint: Imaging at 1,2,3 and 4 hours after the administration of the radiopeptide. Method of measurement: With imaging.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Mohammad Abedi

Mazandaran University of Medical Sciences

mabedi167@yahoo.com+98 11 3332 9628

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026